24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT02182830

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02182830
Other papers using this trial's data
  • Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension Circulation, 2019-04-30 DOI, PubMed 30786754

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02182830. Randomized; double masking; primary purpose treatment. Start 2014-07-25 (actual); primary completion 2017-05-18 (actual). Results posted on 2018-07-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension
Intervention (Drug)
Empagliflozin low dose
Intervention (Drug)
placebo
Intervention (Drug)
Empagliflozin high dose
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02182830
Content hash
eafffc8b1fe5e8628aadc1bba995b292cebbf5d4fe47da9da3c43b08da69acf8